This paper is only available as a PDF. To read, Please Download here.
Eighty percent of medicinal cannabis users are pain patients. Tetrahydrocannabinol
(THC), a main component of cannabis, reduces neuropathic pain at low potency (<15%)
with limited side effects. However, we discovered high potency products (>15% THC)
dominate the legal U.S. cannabis market, medical and recreational. Even though demand
could be a reason for this, financial gain could also play a role. We hypothesize
that there is an association between THC content and price. We tested this hypothesis
in CA since this was the first state to legalize medical cannabis in 1996. We randomly
selected dispensaries across California, screened for a web presence, and noted product
menu, THC content for herbal products, CBD content, price, type of product (flower
or preroll), and chemovar (Sativa, Indica or Hybrid). We observed that more potent
products (>15% THC) were more prevalent and more expensive than low potency (<15%
THC) products. This potency and price association was found in both flower and preroll
products. Similarly, this association was found in Hybrid, and at some extent in Indica,
but not in Sativa products. Flower products have higher THC concentration than preroll
products, however preroll were more expensive than flower products. We did not find
differences in THC content among Sativa, Indica, and Hybrid products. Considering
CBD, high potency THC products with 0% CBD were generally more expensive than those
with CBD; however, for low potency THC products, the presence of CBD increased the
price. High THC content is associated with higher prices in most herbal products,
but some factors influence this association (i.e. preroll, Sativa or CBD). Our data
indicate that economic motives may influence, at least in part, the composition of
medical cannabis market. This study offers evidence to guide policy and help ensure
a safe marketplace for patients. Department of Anesthesiology-Wake Forest School of
Medicine Funds.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.